Comparative Pharmacology
Head-to-head clinical analysis: FLUTEX versus TRIDESILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUTEX versus TRIDESILON.
FLUTEX vs TRIDESILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Flutamide is a nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone (DHT) to androgen receptors in target tissues, thereby blocking the androgenic effects.
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid from membrane phospholipids.
50 mg orally once daily
0.05% ointment or cream applied topically to affected area twice daily.
None Documented
None Documented
Terminal elimination half-life: 24–36 hours, permitting once-daily dosing in chronic therapy
2–3 hours (topical); 1–2 hours (systemic) after IV, with clinical duration prolonged due to tissue binding.
Renal: ~70% (50% unchanged, 20% as metabolites); Biliary/fecal: ~30%
Primarily hepatic metabolism; metabolites excreted renally (70%) and in feces (30%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid